S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
OTCMKTS:NVZMY

Novozymes A/S (NVZMY) Stock Price, News & Analysis

$58.85
-0.50 (-0.84%)
(As of 03/27/2024 ET)
Today's Range
$58.55
$59.01
50-Day Range
$50.49
$61.72
52-Week Range
$38.75
$61.86
Volume
5,666 shs
Average Volume
13,332 shs
Market Capitalization
$27.56 billion
P/E Ratio
37.25
Dividend Yield
0.65%
Price Target
N/A

Novozymes A/S MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-1.00mentions of Novozymes A/S in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
11.92%
From $1.93 to $2.16 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.98 out of 5 stars

NVZMY stock logo

About Novozymes A/S Stock (OTCMKTS:NVZMY)

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S was founded in 1925 and is based in Bagsvaerd, Denmark.

NVZMY Stock Price History

NVZMY Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
DuPont’s stock jumps on dividend hike, stock buyback
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Major shareholder announcement
Novozymes A/S goes ex-dividend tomorrow
Novozymes's Earnings: A Preview
Novozymes swells land holdings in Franklin County
No Major Surprises in Novozymes’ Q4 2022 Results
Novozymes A/S PT Lowered to DKK425 at Berenberg
Novozymes A/S (NVZMF) Q4 2022 Earnings Call Transcript
Novozymes delivers historically strong full-year results
See More Headlines
Receive NVZMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/31/2024
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:NVZMY
Employees
6,756
Year Founded
2000

Profitability

Net Income
$439.08 million
Pretax Margin
21.84%

Debt

Sales & Book Value

Annual Sales
$2.60 billion
Cash Flow
$0.94 per share
Book Value
$4.45 per share

Miscellaneous

Free Float
N/A
Market Cap
$27.56 billion
Optionable
Not Optionable
Beta
0.82

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Ms. Ester Baiget (Age 53)
    President & CEO
    Comp: $2.8M
  • Mr. Rainer Lehmann (Age 49)
    Executive VP & CFO
    Comp: $753.47k
  • Mr. Anders Lund (Age 51)
    Chief Operating Officer
    Comp: $912.86k
  • Mr. Claus Crone Fuglsang (Age 56)
    Chief Scientific Officer
  • Mr. Tobias Cornelius Bjorklund
    Head of Investor Relations
  • Ms. Winnie Hoejvang Bugel (Age 59)
    General Counsel of Legal
  • Mr. Tue Micheelsen
    Vice President of Global Sales & Marketing
  • Mr. Morten Enggaard Rasmussen (Age 48)
    Executive Vice President of People & Stakeholder Relations
  • Ms. Tina Sejersgaard Fano (Age 55)
    Executive Vice President of Planetary Health Biosolutions
    Comp: $898.37k
  • Ms. Amy Byrick (Age 50)
    Executive Vice President of Human Health Biosolutions

NVZMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Novozymes A/S stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NVZMY shares.
View NVZMY analyst ratings
or view top-rated stocks.

How have NVZMY shares performed in 2024?

Novozymes A/S's stock was trading at $54.9050 on January 1st, 2024. Since then, NVZMY shares have increased by 7.2% and is now trading at $58.85.
View the best growth stocks for 2024 here
.

Are investors shorting Novozymes A/S?

Novozymes A/S saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,600 shares, an increase of 176.9% from the February 29th total of 1,300 shares. Based on an average trading volume of 27,700 shares, the days-to-cover ratio is currently 0.1 days.
View Novozymes A/S's Short Interest
.

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMY) released its quarterly earnings data on Wednesday, January, 31st. The biotechnology company reported $0.36 earnings per share for the quarter, missing analysts' consensus estimates of $0.47 by $0.11. The biotechnology company earned $664.46 million during the quarter. Novozymes A/S had a trailing twelve-month return on equity of 21.42% and a net margin of 16.88%.

How often does Novozymes A/S pay dividends? What is the dividend yield for Novozymes A/S?

Novozymes A/S declared an annual dividend on Thursday, October 12th. Investors of record on Monday, October 23rd will be given a dividend of $0.384 per share on Wednesday, November 1st. The ex-dividend date of this dividend is Friday, October 20th.
Read our dividend analysis for NVZMY
.

Is Novozymes A/S a good dividend stock?

Novozymes A/S (OTCMKTS:NVZMY) pays an annual dividend of $0.38 per share and currently has a dividend yield of 0.65%. The dividend payout ratio is 24.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVZMY will have a dividend payout ratio of 17.59% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVZMY.

What ETFs hold Novozymes A/S's stock?

ETFs with the largest weight of Novozymes A/S (OTCMKTS:NVZMY) stock in their portfolio include Putnam BioRevolution ETF (SYNB).Emerge EMPWR Sustainable Global Core Equity ETF (EMZA).

How do I buy shares of Novozymes A/S?

Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Novozymes A/S have any subsidiaries?
The following companies are subsidiares of Novozymes A/S: Allopartis, Beta Renewables S.p.A., Delta Biotechnology, Earth BioSciences, Grundejerforeningen Hallas Park, Grundejerforeningen Smørmosen, Iogen Bio-Products, MagnaBioAnalytics LLC, Microbiogen PTY Ltd., Natural Industries, Novozymes (China) Biotechnology Co. Ltd., Novozymes (China) Investment Co. Ltd., Novozymes (Shenyang) Biologicals Co. Ltd., Novozymes (Thailand) Limited, Novozymes Australia Pty. Ltd., Novozymes Belgium BVBA, Novozymes BioAg A/S, Novozymes BioAg Inc., Novozymes BioAg Limited, Novozymes BioAg Productos Para Agricultura Ltda., Novozymes BioAg S.A., Novozymes Bioindustrial A/S, Novozymes Bioindustrial China A/S, Novozymes Biologicals Inc., Novozymes Biopharma DK A/S, Novozymes Blair Inc., Novozymes Canada Limited, Novozymes Deutschland GmbH, Novozymes Enzim Dis Ticaret Ltd., Novozymes France S.A.S, Novozymes Hong Kong Ltd., Novozymes Inc., Novozymes Italia S.r.l., Novozymes Japan Ltd., Novozymes Korea Limited, Novozymes Latin America Ltda., Novozymes Malaysia Sdn. Bhd., Novozymes Mexicana S.A. de C.V., Novozymes Mexico S.A. de C.V., Novozymes Nederland B.V., Novozymes North America Inc., Novozymes RUS LLC, Novozymes Singapore Pte. Ltd., Novozymes South Africa (Pty) Ltd., Novozymes South Asia Pvt. Ltd., Novozymes Spain S.A., Novozymes Sweden AB, Novozymes Switzerland AG, Novozymes Switzerland Holding AG, Novozymes UK Ltd, Novozymes US Inc., OrganoBalance GmbH, Pacific Vet Group-USA, Philom Bios, PrecisionBiotics Group Limited, Qingdao Huayuan Fine Bio-Products, Suzhou Hongda Enzyme Co. Ltd., Sybron Biochemicals, TJ Technologies, and Turfal Indústria e Comércio de Produtos Agrônomicos e Biológicos.
Read More
This page (OTCMKTS:NVZMY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners